R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Vice President - Global Environmental Health & Safety

Full-Time
$294k - $367k+ Equity awards
Expert
Bachelor's, Master's, MBA
Redwood City, CA, USA
HybridOnsite at the Redwood City headquarters; willingness to travel domestically and internationally.
Facilities OperationsEnvironmental Health & Safety

About the job

Requirements
  • A Bachelor of Science or Bachelor of Arts degree in Environmental Health & Safety, industrial hygiene, occupational safety, environmental science, engineering, life sciences, or a related discipline is required; an advanced degree is preferred.
  • At least 18 years of progressively responsible EHS experience, including significant executive-level leadership in the global pharmaceutical industry.
  • Demonstrated experience leading EHS for a multinational pharmaceutical company operating across multiple countries and regions, with direct accountability for global strategy, governance, regulatory compliance, audit and assurance, incident management, and executive reporting.
  • At least 10 years of people-leadership experience, including building, scaling, and leading global or regional EHS teams across a complex, matrixed organization.
  • Demonstrated experience supporting research laboratories, clinical development, technical operations, external manufacturing, supply chain, corporate offices, and commercial or medical field organizations.
  • Demonstrated experience opening and integrating international offices or facilities, establishing EHS programs in new countries, and translating enterprise standards into locally compliant requirements.
  • Demonstrated experience managing EHS for a worldwide, mobile, and field-based workforce, including global sales, medical affairs, market access, or comparable commercial organizations.
  • Deep knowledge of U.S. EHS requirements, including OSHA, EPA, and Cal/OSHA, and strong working knowledge of international EHS regulatory frameworks, including the ability to govern compliance through regional leaders and local subject-matter experts.
  • Demonstrated leadership of ESG or corporate sustainability programs within a global pharmaceutical or similarly regulated life-sciences company, including strategy development, governance, metrics, target setting, disclosure, data controls, and executive or Board reporting.
  • Ability to communicate complex risk, regulatory, and operational issues clearly to the Board, senior executives, employees, regulators, investors, and external partners.
  • Strong business judgment and change-management capability, with demonstrated success prioritizing risk and investment in a fast-paced, high-growth, science-driven organization.
  • Ability and willingness to travel domestically and internationally.
Responsibilities
  • Define the enterprise EHS vision, multi-year roadmap, policies, standards, and operating model for a global pharmaceutical company, aligned with pipeline advancement, clinical development, commercialization, product launch, and international growth.
  • Lead EHS due diligence for new offices and facilities worldwide; align with local and global teams on site-selection criteria, design reviews, permitting, pre-occupancy readiness, emergency planning, and operational launch support; establish repeatable global expansion playbooks.
  • Develop scalable EHS programs for the worldwide workforce, including field sales, medical affairs, market access, remote and hybrid employees, frequent travelers, and employees working in healthcare, customer, conference, and third-party environments. Establish duty-of-care expectations for travel, lone work, driving, ergonomics, emergency response, and country-specific occupational health requirements.
  • Integrate EHS risk into enterprise risk management, business planning, capital allocation, business continuity, crisis management, insurance, and executive decision-making.
  • Maintain a risk-based global compliance framework for occupational safety, environmental protection, fire and life safety, hazardous materials and waste, biosafety, transportation, contractor safety, and occupational health. Translate global standards into locally compliant programs and support effective audit, assurance, and management-review processes.
  • Advise executive leadership and the Board, as appropriate, on material risks, emerging regulatory trends, performance, crisis response, and investment priorities; build a prevention-first culture that advances toward predictive risk management and operational excellence.
  • Build, lead, and develop a high-performing global EHS organization and regional network of employees, site leaders, consultants, and service providers. Establish decision rights, accountabilities, succession plans, and capability-development programs across countries and business functions.
  • Establish enterprise metrics, dashboards, management reviews, audit protocols, corrective-action governance, and executive reporting. Benchmark performance across sites and regions and use leading indicators, trend analysis, and risk intelligence to identify systemic issues and drive continuous improvement.
  • Ensure timely escalation, investigation, root-cause analysis, corrective action, and organizational learning for incidents and near misses worldwide. Provide executive leadership during significant EHS events, regulatory inspections, public-health events, and business disruptions.
  • Provide strategic oversight for laboratory, office, and technical-operations safety programs, including chemical and biological safety, industrial hygiene, process and equipment safety, hazardous materials and waste, electrical safety, lockout/tagout, hot work, contractor safety, ergonomics, occupational health, indoor environmental quality, and emergency response.
  • Own the integrity and governance of EHS- and sustainability-related ESG data, including definitions, methodologies, internal controls, source documentation, validation, and executive certification. Lead relevant content for corporate responsibility reports, investor and customer questionnaires, ratings and benchmarking submissions, and required or voluntary disclosures; coordinate readiness for internal audit and independent assurance.
  • Develop a risk-based roadmap for greenhouse-gas emissions, energy, water, waste, hazardous materials, climate resilience, and responsible resource use across owned and leased locations and the pharmaceutical value chain. Establish baselines, targets, and performance plans, including Scope 1 and 2 emissions and, as appropriate, material Scope 3 categories involving suppliers, CDMOs, CROs, logistics providers, business travel, and other partners.
Desired Qualifications
  • A Master of Arts or Master of Science, MBA, or other relevant advanced degree.
  • Professional certification such as CSP, CIH, CHMM, or an equivalent international credential.
  • Experience implementing and sustaining global EHS management systems aligned with ISO 45001 and ISO 14001.
  • Experience engaging with global regulators, works councils, occupational-health providers, insurers, and external assurance partners.
  • Working knowledge of ESG and sustainability frameworks and disclosure regimes relevant to multinational companies, including the GHG Protocol, ISSB/IFRS S1 and S2, TCFD-aligned climate disclosure, CDP, GRI, SASB industry standards, and applicable U.S. and international climate- and sustainability-reporting requirements.
  • Experience developing greenhouse-gas inventories and reduction roadmaps, evaluating Scope 3 emissions, engaging suppliers and external manufacturing partners, and preparing ESG information for third-party assurance, investor review, or public reporting.
  • Multilingual capability.

About the company

Revolution Medicines develops targeted therapies for cancers caused by RAS mutations, which are found in about 30% of human cancers. The company’s products are small molecules called RAS(ON) inhibitors that work by blocking the active, cancer-promoting form of the RAS protein to stop tumor growth. Unlike older treatments that could only target a few specific mutations, this platform creates inhibitors that can address a much wider range of RAS-driven cancers. The company's goal is to advance these candidates through clinical trials to provide effective treatment options for patients with previously "undruggable" forms of cancer.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Get referred to Revolution Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved RASONQUE on August 26, 2026, six months ahead of deadline.
  • RASolute 302 cut death risk 60% and doubled median overall survival to 13.2 months.
  • Royalty Pharma's June 2025 $2 billion package funds commercialization and global expansion through 2027.

What critics are saying

  • RASONQUE costs $39,800 monthly, inviting Medicare and commercial payer restrictions in 2026.
  • Revenue still depends overwhelmingly on one launch; any RASONQUE setback crushes the company.
  • AstraZeneca, Amgen, and Mirati pressure RAS programs; resistance or safety issues can erase the franchise.

What makes Revolution Medicines unique

  • RASONQUE became the first approved broad RAS(ON) inhibitor on August 26, 2026.
  • Revolution Medicines avoids companion diagnostics and treats metastatic PDAC with or without RAS mutations.
  • Its pipeline spans daraxonrasib, elironrasib, and zoldonrasib across pancreatic, lung, and colorectal cancers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Asianet News
Oct 16th, 2026
VSTM stock clocks best day in 11 months after positive cancer drug trial update and multiple price-target hikes.

VSTM stock clocks best day in 11 months after positive cancer drug trial update and multiple price-target hikes. Published: Oct 16 2026, 03:00 AM IST * FB * TW * Linkdin * Whatsapp * GNFollow Us * Alliance Global on Thursday raised its price target on VSTM to $22 from $18 and maintained a Buy rating. * RBC Capital analyst Leonid Timashev said that while VS-7375 tolerability is not as favorable as Revolution Medicines' experimental drug Zoldonrasib, the overall profile remains acceptable. * BTIG said VS-7375 could rival Revolution Medicines' approved drug Daraxonrasib in second-line metastatic pancreatic disease. Shares of Verastem Oncology (VSTM) jumped 20% on Thursday, clocking its best day since Nov. 2025, as analysts lifted price targets following a positive update on the company's experimental drug VS-7375 in second-line metastatic pancreatic ductal adenocarcinoma. On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose, along with responses in lung and colorectal cancers and a manageable safety profile dominated by low-grade gastrointestinal side effects. Verastem also added that the company has aligned with the U.S. Food and Drug Administration on a late-stage path in first-line metastatic pancreatic cancer using chemotherapy-free regimens, with the study expected to open by year-end. Wall street weighs in on VSTM. Alliance Global on Thursday subsequently raised its price target to $22 from $18 and maintained a Buy rating, describing the updated TARGET-D 101 data as showing a highly tolerable safety profile and efficacy that is in line with or better than other drugs in the same class and in development, potentially best-in-class. RBC Capital analyst Leonid Timashev increased the target to $19 from $14 while keeping an Outperform rating, calling the drug clearly active with hints of best-in-class efficacy in pancreatic ductal adenocarcinoma. He noted that while tolerability is not as favorable as one competitor, Revolution Medicines' experimental drug Zoldonrasib, the overall profile remains acceptable. BTIG raised its target to $24 from $18 and kept a Buy rating, saying the detailed update across second-line pancreatic cancer, second-line non-small cell lung cancer, and third-line colorectal cancer points to class-leading efficacy that could rival Revolution Medicines' approved drug Daraxonrasib in second-line metastatic pancreatic disease. Jefferies analyst Faisal Khurshid raised the price target to $13 from $11 and maintained a Buy rating. Aligning on a favorable late-stage trial path, he added, positions Verastem only about seven months behind competitors Revolution Medicines and Incyte in the race to develop drugs within the same class. CEO change and Capital raising. Verastem on Wednesday also priced a $250 million offering of common stock and pre-funded warrants at $8 per share to support VS-7375 development and general purposes, expected to close around October 15. The company further announced a planned CEO transition, with longtime executive Daniel Paterson retiring effective January 1, 2027, and board member Michael P. Bailey succeeding him. How did VSTM retail traders react? On Stocktwits, retail sentiment around VSTM stayed within 'extremely bullish' territory over the past 24 hours, while message volume stayed at 'extremely high' levels. "The more I watch it, the more constructive it looks," a Stocktwits user wrote about the stock. View this Stocktwits post Another user drew a parallel between VSTM's current rally and Iovance Biotherapeutics Inc (IOVA) stock's rally last month, which lasted for several days. View this Stocktwits post VSTM stock has gained 2o% year-to-date. For updates and corrections, email newsroom[at]stocktwits[dot]com.< Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business. 0 Comments / 0 New

pharmaphorum
Oct 16th, 2026
RevMed nears EU okay for pancreatic cancer drug Rasonque.

RevMed nears EU okay for pancreatic cancer drug Rasonque. Revolution Medicines is likely just weeks away from getting EU approval for its oral RAS inhibitor Rasonque as a treatment for pancreatic cancer, after the drug was recommended by the EMA's human medicines committee. The CHMP has backed Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one previous treatment - the same indication that was cleared by the US FDA in August. The positive opinion is based on phase 3 results with Rasonque from the RASolute 302 trial that caused a stir at this year's ASCO cancer congress, with a doubling in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy and big improvements in quality-of-life scores. The outcome was remarkable, particularly as metastatic pancreatic adenocarcinoma is a notoriously difficult-to-treat cancer with a low survival rate. "People with metastatic pancreatic adenocarcinoma whose disease has worsened after prior treatment have limited treatment options and a poor prognosis," said the EMA, which granted Rasonque an expedited, phased review - which cut its assessment time from 210 days to less than 150 days - as a high-priority medicine that could address this unmet medical need. "Given the seriousness of the disease, [and] the limited efficacy and substantial toxicity of standard-of-care chemotherapy, there is a need for better treatment options for these patients." The RAS protein is a key driver for many tumour types, including the majority of pancreatic cancers. For many years, it was considered an 'undruggable' target, until RevMed solved the problem with daraxonrasib, constructed by binding RAS to a protein called cyclophilin A to form a complex that can attach to the RAS protein and block its activity. The pan-RAS category is pretty crowded, with more than a dozen drug candidates in clinical testing, but Revolution seems to have a healthy first-mover advantage with other trials underway in pancreatic adenocarcinoma, as well as non-small cell lung cancer (NSCLC). Those include the RASolute 303 trial in first-line pancreatic cancer, RASolute 304 in adjuvant treatment of tumours treatable with surgery, and RASolve 301 looking at first-, second-, and third-line treatment of metastatic NSCLC. There has been some noise about Rasonque's slightly lower tumour response rate in patients with KRAS G12D mutations in RASolute 302, which analysts have suggested could open the door to competition from selective drugs like Verastem Oncology's VS-7375, which is in phase 3 for pancreatic cancer. RevMed is, however, also developing a KRAS G12D-selective inhibitor, zoldonrasib, both as a monotherapy and in combination with Rasonque. 16 October, 2026

Yahoo Finance
Oct 15th, 2026
Revolution Medicines and Oruka double in 2026, beating Magnificent Seven; analysts see up to 95% upside

Two biotech stocks, Revolution Medicines and Oruka Therapeutics, have more than doubled this year, beating most of the Magnificent Seven tech group. Wall Street's average price targets suggest further gains. Revolution Medicines won approval for Rasonque, a treatment for certain patients with metastatic pancreatic cancer. In a Phase 3 study, patients lived a median 13.2 months, against 6.7 months on chemotherapy. Its market cap is about $41 billion, and its average price target of $259.14 implies 35.7% upside. Oruka Therapeutics has no approved drug. Its psoriasis candidate, ORKA-001, could be dosed once or twice a year, and has shown strong results in a Phase 2a study. The average price target of $155 implies 95% upside, but the drug has not entered Phase 3 trials.

Yahoo Finance
Oct 15th, 2026
EU regulator backs Revolution Medicines' RASONQUE for pancreatic cancer after 60% lower death risk

Revolution Medicines (Nasdaq: RVMD) said the European Medicines Agency's Committee for Medicinal Products for Human Use has backed RASONQUE (daraxonrasib), an oral tablet for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy. If the European Commission approves it, RASONQUE would be the first broad RAS-targeted treatment option in the European Union for these patients. The opinion followed an expedited review under the agency's Cancer Medicines Pathfinder project. In the Phase 3 RASolute 302 trial, the drug cut the risk of death by 60% compared with chemotherapy. Median overall survival was 13.2 months, against 6.7 months for chemotherapy. The US Food and Drug Administration approved the drug on August 26, 2026.

PR Newswire
Oct 14th, 2026
Cancer drug spending to top $400B by 2028 as RAS-targeted therapies reach pancreatic, colorectal cancers

Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute. The US accounts for roughly 46% of the total. On August 26, the US Food and Drug Administration (FDA) approved Revolution Medicines' RASONQUE (daraxonrasib), the first broad RAS-targeted medicine for metastatic pancreatic cancer. In a Phase 3 trial, median overall survival was 13.2 months, against 6.7 months with chemotherapy. Colorectal cancer is also drawing attention. Oncolytics Biotech expects interim data from Part A of its REO 033 study of pelareorep by year-end. Exelixis saw the FDA extend its review of zanzalintinib for metastatic colorectal cancer to March 3, 2027.